Table 1.

Association between PCSK9 monoclonal antibodies and the risk of new-onset diabetes mentioned in the manuscript.

Trail	N	Duration	Target population	Study groups	Change of lipid profile	Change of glucose spectrum	Risk of new-onset diabetes incidence VS placebo
Open-Label OSLER-1 Extension Study [75]	1,324	≥208weeks	–	Evolocumab, 420 mg monthly	LDL-C decreased by 58%	FPG did not change significantly	No significant difference
FOURIER randomized controlled trial [76]	27,564	2.2 years	Patients with ASCVD and LDL-C ≥1.8 mmol/L	Evolocumab, 140 mg fortnightly or 420 mg monthly	LDL-C decreased by 59%, non-HDL decreased by 52% Apo B decreased by 49%	HbA1c and FPG did not change significantly	No significant Difference (HR of 1.05; 95% CI, 0.94 to 1.17)
GLAGOV Randomized Clinical Trial [77]	968	78 weeks	Patients with angiographic coronary disease treating statins	Evolocumab, 420 mg monthly	LDL-C decreased by 60.7%	Glucose and HbA1c did not change significantly	No significant difference
FOURIER randomized controlled trial [78]	2,341	78 weeks	Patients with LDL-C ≥1.8 mmol/L and a maximum tolerated dose of statins at high risk of cardiovascular events	Alirocumab, 150 mg fortnightly	LDL-C decreased by 62%	No information	No significant Difference (P = 0.84)
ODYSSEY FH I and FH II [79]	735	78 weeks	Patients with familial hypercholesterolemia and LDL-C ≥1.8 mmol/L	Alirocumab, 75 mg fortnightly	LDL-C decreased by 57.9% (FH I) and 51.4% (FH II)		No significant difference
Meta-analysis [80]	26,123	–	–	Alirocumab or Evolocumab	No information	FPG and HbA1c did not change significantly	No significant difference(HR of 1.05; 95% CI, (0.95–1.16)
Meta-analysis [81]	65,957	≥12 weeks	–	Alirocumab or Evolocumab	No information		No significant difference (HR of 0.97; 95% CI, 0.91–1.02; P = 0.22)
Meta-analysis [82]	68,123	78 weeks	–	Alirocumab, Evolocumab, or Bococizumab	No information	FPG and HbA1c increased	No significant difference (HR of 1.04; 95% CI, 0.96–1.13; P = 0.427)